You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰格醫藥超購逾413倍,逾32萬人認購,上限100港元定價
uSMART友信智投 08-03 16:02

uSMART友信智投8月3日消息,泰格醫藥今日午間發佈公告稱,港股發售價定為每股H股100港元,此定價相較今日A股股價106元約折價15%。

此外,市場消息透露,泰格醫藥初步已錄得413倍超額認購,凍結資金2465億港元,凍資額排名今年新股第五位。集資107.0651億港元,有32萬人認購

資料來源:信報

由於認購倍數超過96倍,故泰格醫藥啟動回撥機制最大一檔,令公開發售股數佔比增至21.5%,即甲乙組分別分配約11.5萬手

分析認為,泰格醫藥基本面良好,值得長期投資,料首日升幅介乎5%至10%,但需留意其A股走勢。

泰格醫藥將於週四(6日)公佈中簽結果,7日掛牌,保薦人為美銀證券、海通國際、中信證券、中金。

 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account